Safety and efficacy results for upadacitinib (Rinvoq) in combination with topical corticosteroids for moderate-to-severe atopic dermatitis in adolescent and adult participants were published on 2021-01-01. This pivotal publication, known as the AD Up study, provides important data on the drug's performance in this patient population.
Background
The published study, referred to as AD Up, focused on evaluating upadacitinib (Rinvoq) in the context of moderate-to-severe atopic dermatitis. This condition, characterized by chronic inflammation of the skin, often requires comprehensive treatment strategies. The investigation specifically examined the drug's safety and efficacy when administered alongside topical corticosteroids, a common component of atopic dermatitis management, for both adolescent and adult patients.
What this means
The publication of the AD Up study results offers a comprehensive look at the safety and efficacy profile of upadacitinib (Rinvoq) when used as a combination therapy with topical corticosteroids. This information is critical for healthcare professionals, researchers, and patient advocacy groups seeking to understand the potential benefits and risks of this treatment approach for adolescents and adults living with moderate-to-severe atopic dermatitis. The availability of these data supports informed decision-making regarding treatment options for this challenging dermatological condition.
Source
The detailed findings regarding upadacitinib's safety and efficacy in the AD Up study were made publicly available through a publication indexed on PubMed. The article, titled "Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): res (Lancet)", was published on 2021-01-01. The full text and abstract can be accessed via the National Library of Medicine's PubMed database at pubmed.ncbi.nlm.nih.gov.